MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS, Katarina GAZDIKOVA, Monika LABUDOVA, Martin CAPRNDA, Robert PROSECKÝ, Jozef DRAGASEK, Peter KRUŽLIAK a Roman DATS. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics. Clinical Biochemistry. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2023, roč. 116, June 2023, s. 120-127. ISSN 0009-9120. Dostupné z: https://dx.doi.org/10.1016/j.clinbiochem.2023.04.011.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics
Autoři MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS, Katarina GAZDIKOVA, Monika LABUDOVA, Martin CAPRNDA, Robert PROSECKÝ (203 Česká republika, domácí), Jozef DRAGASEK, Peter KRUŽLIAK (703 Slovensko, garant, domácí) a Roman DATS.
Vydání Clinical Biochemistry, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2023, 0009-9120.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.800 v roce 2022
Kód RIV RIV/00216224:14110/23:00131199
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.clinbiochem.2023.04.011
UT WoS 001005720800001
Klíčová slova anglicky Prostate cancer; Diagnostics; RNA; PCA3; TMPRSS2; ERG; HOXC6; DLX1; Urinary marker
Štítky 14110116, 14110121, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 11. 7. 2023 09:08.
Anotace
Background: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. To date, the role of the combined application of long non-coding RNAs (PCA3, DLX1, HOXC6, TMPRSS2:ERG) for obtaining the most accurate method of detection of PCa has not yet been comprehensively investigated.Methods: In total 240 persons were included in the retrospective study. Among them were 150 patients with confirmed PCa, 30 patients with benign prostatic hyperplasia, 30 patients with active chronic prostatitis and 30 healthy volunteers. In all patients, the urine samples were collected prior to biopsy or treatment. Polymerase chain reaction with reverse transcription was performed to detect the expression level of PCA3, HOXC6, DLX1 and the presence of the TMPRSS2:ERG transcript.Results: PCA3 was detected in urine samples in all cases. Using a PCA3 score of 56 allowed the differentiation between PCa and all other cases with a sensitivity of 61% and specificity of 96% (p < 0.001) while a PCA3 score threshold value of 50 resulted in a differentiation between clinically significant PCa (ISUP grades 2-5) and all other cases with a sensitivity of 93% and specificity of 93% (p < 0.001). The TMPRSS2:ERG expression in urine was detected exclusively in the group of patients with PCa and only in 16% of all cases.Conclusions: PCA3 score detected in urine demonstrated moderate sensitivity and good specificity in differenti-ation between PCa and non-PCa and high sensitivity and specificity in differentiation between clinically sig-nificant PCa and non-PCa.
VytisknoutZobrazeno: 24. 7. 2024 12:30